eligibility_summary
Adults ≥18 with confirmed FL grade 1–3A, ≥1 prior anti‑CD20–based systemic therapy, need systemic tx, measurable (≥2 cm) disease, ECOG ≤2, adequate renal (CrCl >60 P1/≥30 P2), marrow, liver, coagulation, contraception/REMS/consent. Exclude: transformed/3B, recent therapy/surgery/radiation, lenalidomide refractory/intolerant/recent, recent SCT, CNS disease, prior EZH inhibitor, CYP3A/P‑gp drugs, active HIV/HBV/HCV/infection, cardiac/ECG issues, other malignancy ≤2y, steroids >10 mg, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2 single-arm study in relapsed/refractory follicular lymphoma testing valemetostat + rituximab + lenalidomide (R2). Valemetostat: oral small-molecule dual EZH1/EZH2 histone methyltransferase inhibitor (epigenetic), lowers H3K27me3 to reverse PRC2-mediated gene silencing in malignant B cells. Rituximab: IV anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis. Lenalidomide: oral immunomodulatory drug (IMiD) that binds cereblon, promotes IKZF1/3 degradation, enhances T- and NK-cell activity, and has anti-angiogenic effects. Targets: CD20+ follicular lymphoma B cells, PRC2/EZH1/2 pathway, CRBN-IKZF1/3 axis, immune microenvironment (NK/T-cell mediated cytotoxicity and ADCC).